Genitourinary Syndrome of Menopause (GSM): Emergency Symptoms, Daily Management, and What Every Woman Should Know

What Is GSM and Why Does It Happen?

GSM is not just vaginal dryness. It is a whole-system response to estrogen loss that affects the vaginal walls, vulva, urethra, and bladder. Without estrogen, the vaginal epithelium thins, glycogen stores drop, the protective lactobacillus-dominant microbiome shifts, and vaginal pH rises from roughly 3.5 to above 5. The result is a self-reinforcing cycle of dryness, inflammation, microabrasion, and pain.

Estrogen receptors are densely expressed throughout the genitourinary tract, which is why the tissue changes are so consistent and why local estrogen therapy reverses them reliably.

Unlike vasomotor symptoms such as hot flashes, GSM does not improve spontaneously over time. It worsens with each year of estrogen deprivation unless treated. That distinction matters clinically: a woman who waits five years before starting treatment may find her vaginal anatomy significantly changed, with tissue fragility, introital narrowing, and adhesion formation.

Who Gets GSM

GSM is most common after natural or surgical menopause, but it is not exclusive to older women.

• Postmenopausal women. This is the largest group. Approximately 45 to 50 percent of postmenopausal women report at least one moderate-to-severe GSM symptom.
• Women on aromatase inhibitors or GnRH agonists. Cancer survivors and women treated for endometriosis or fibroids with ovarian suppression develop estrogen-deficiency symptoms rapidly. Symptoms may appear within weeks of starting these medications.
• Perimenopausal women. Estrogen levels fluctuate widely in perimenopause. Some women notice the first episodes of vaginal dryness or dyspareunia years before their final menstrual period.
• Postpartum and breastfeeding women. Lactation suppresses estrogen significantly. Vaginal dryness during breastfeeding is common and resolves after weaning in most women. This is physiological, not true GSM, but the symptom overlap is significant.

The Anatomy of the Problem

The normal vaginal wall has four layers. Estrogen maintains epithelial thickness, collagen content, and elastin fibers. Estrogen loss causes the superficial and intermediate cell layers to thin, reducing rugation and elasticity. The submucosal connective tissue loses collagen and water. Blood supply decreases.

The urethra and bladder trigone share the same embryological origin as the vagina and carry the same estrogen receptors. This is why GSM produces urinary symptoms alongside vaginal ones: urgency, frequency, recurrent urinary tract infections (UTIs), and dysuria are all part of the syndrome, not separate coincidences.

GSM Emergency Symptoms: When to Call 911 or Go to the Emergency Room

Most GSM symptoms are chronic and manageable with outpatient care. A small number of presentations require urgent or emergency evaluation. Knowing the difference protects you.

Symptoms That Are True Emergencies

Call 911 or go to your nearest emergency room immediately if you experience any of the following.

Heavy or unexplained vaginal bleeding. Postmenopausal bleeding is never normal. GSM causes contact bleeding from fragile tissue, but this is typically light spotting. Any significant postmenopausal vaginal bleeding must be evaluated promptly to rule out endometrial cancer, which is the most common gynecologic cancer in women in the United States. Heavy bleeding, defined as soaking more than one pad per hour for two or more consecutive hours, warrants emergency care.

Fever above 38.5 degrees C (101.3 F) with pelvic pain, vaginal discharge, or urinary symptoms. This combination may signal a serious ascending infection, pelvic inflammatory disease (less common postmenopausally but possible), or a complicated UTI progressing toward urosepsis. Urosepsis carries a mortality rate exceeding 20 percent in older women and can escalate rapidly.

Signs of sepsis. Confusion, rapid breathing, heart rate above 100 beats per minute, low blood pressure, or mottled skin alongside urinary or pelvic symptoms requires 911. Do not drive yourself.

Inability to urinate (urinary retention). Acute urinary retention can occur when severe urethral atrophy causes tissue collapse or when infection causes edema. It is painful and requires catheterization within hours to prevent bladder damage.

Severe acute vulvar or vaginal pain. GSM causes chronic discomfort, not sudden severe unilateral pain. Sudden severe pain may indicate a Bartholin gland abscess, hematoma after trauma, or a skin condition such as lichen sclerosus with secondary superinfection.

Symptoms That Need an Urgent Appointment (Within 48 Hours)

These are not 911 situations but should not wait for a routine appointment.

• Visible skin ulceration or open sores on the vulva
• Purulent vaginal discharge with odor
• Burning urination with blood in the urine (hematuria)
• Significant new asymmetric vulvar swelling
• Postmenopausal spotting after intercourse (needs ruling out of endometrial pathology)

What GSM Does NOT Cause

GSM does not cause chest pain, leg swelling, shortness of breath, or neurological symptoms. If you have these alongside vaginal or urinary complaints, the emergency is cardiovascular or neurological, not gynecological.

Diagnosing GSM: What Your Clinician Is Looking For

GSM is a clinical diagnosis. No laboratory test is required, though a vaginal pH above 5 and a maturation index showing predominantly parabasal cells on a vaginal smear support the diagnosis.

Your clinician will look for: pallor of the vaginal walls, loss of rugation, petechiae or contact bleeding on speculum insertion, urethral caruncle (a red fleshy protrusion at the urethral meatus, common postmenopausally and almost always benign), and reduced introital caliber.

The Menopause Society's 2023 position statement on GSM recommends that clinicians assess GSM symptoms at every menopause-related visit because women frequently do not raise the topic themselves. Fewer than 25 percent of women with GSM symptoms discuss them with a healthcare provider, often due to embarrassment or the mistaken belief that discomfort is an unavoidable part of aging.

The WomanRx GSM Symptom Severity Framework (developed for clinical triage by our editorial board):

| Severity tier | Key features | Recommended action | |---|---|---| | Emergency | Heavy bleeding, sepsis signs, urinary retention, acute severe pain | 911 or ER now | | Urgent | Ulceration, purulent discharge, hematuria, postmenopausal spotting | Clinician within 48 hours | | Routine | Dryness, mild dyspareunia, urgency, frequency, mild burning | Scheduled telehealth or in-office visit | | Self-care adjunct | Mild dryness only, no bleeding, no infection signs | OTC moisturizer while awaiting appointment |

First-Line Treatments for GSM: The Evidence

Low-dose vaginal estrogen is the most studied, most effective, and most recommended treatment for GSM. If you have GSM symptoms, you should know what is available, what the evidence shows, and how to have a productive conversation with your clinician.

Low-Dose Vaginal Estrogen

Low-dose vaginal estrogen comes in four forms: cream (conjugated equine estrogen or estradiol), tablet or suppository (estradiol 10 mcg), ring (estradiol 7.5 mcg per day release), and gel (estradiol 0.005 percent, approved 2018).

The REJOICE trial, a phase 3 RCT of 764 postmenopausal women, showed that the vaginal estradiol softgel capsule significantly improved vulvovaginal irritation, dryness, and dyspareunia versus placebo over 12 weeks. Symptom improvement begins within two to four weeks and continues over months.

ACOG Practice Bulletin 141 recommends low-dose vaginal estrogen as first-line therapy for women whose primary symptoms are genitourinary, and the same recommendation appears in The Menopause Society's 2023 GSM position statement.

Systemic estrogen absorption from low-dose vaginal products is minimal. Serum estradiol levels remain at or below the postmenopausal reference range of <20 pg/mL for most products. A 2018 pharmacokinetic study published in Menopause found that the 10-mcg vaginal estradiol tablet produced mean serum estradiol concentrations of 4.8 pg/mL after 12 weeks of twice-weekly use, well within the postmenopausal range.

Vaginal DHEA (Prasterone)

Prasterone (Intrarosa) is a synthetic form of dehydroepiandrosterone (DHEA) inserted vaginally once daily. Vaginal cells convert DHEA locally into estrogen and testosterone without meaningful systemic absorption.

The phase 3 AMAG trial demonstrated that 0.5 percent prasterone vaginal insert reduced dyspareunia severity scores by 1.42 points on a 4-point scale versus 0.96 for placebo over 12 weeks. This is a meaningful option for women who prefer to avoid exogenous estrogen entirely, including some breast cancer survivors (though oncologist input is required before starting any hormonal vaginal therapy after breast cancer).

Ospemifene (Oral)

Ospemifene (Osphena) is a selective estrogen receptor modulator (SERM) taken orally at 60 mg daily. It acts as an estrogen agonist in vaginal tissue and as an estrogen antagonist in the uterus and breast.

In the OSPHENA phase 3 trial, ospemifene reduced the most bothersome symptom (vaginal dryness or dyspareunia) significantly compared with placebo, with a favorable vaginal maturation index at 12 weeks. It is an option when women prefer an oral agent, though it carries a small increased risk of hot flashes and venous thromboembolism and should not be used with systemic estrogen.

Non-Hormonal Vaginal Moisturizers and Lubricants

Non-hormonal options do not reverse the underlying tissue changes but manage symptoms effectively for many women.

• Vaginal moisturizers (Replens, Revaree hyaluronic acid gel) used regularly two to three times per week reduce dryness and lower vaginal pH. A 2018 RCT in Menopause found hyaluronic acid vaginal gel non-inferior to estriol vaginal cream for dryness and dyspareunia symptoms over 8 weeks.
• Lubricants used during sexual activity reduce friction and pain but do not change the tissue. Choose water-based or silicone-based options; avoid glycerin-containing products if you are prone to yeast infections.

Non-hormonal options are the preferred starting point for women with active estrogen-receptor-positive breast cancer and for women in the postpartum and breastfeeding period when vaginal dryness is physiological and temporary.

Laser and Energy-Based Therapies

Vaginal CO2 laser and radiofrequency devices have been marketed for GSM. The current evidence base is limited, with mostly small, unblinded trials. The FDA issued a safety communication in 2018 warning that energy-based devices for vaginal rejuvenation have not been proven safe or effective, and The Menopause Society does not recommend them as standard care outside of a clinical trial setting.

GSM Across Life Stages: How the Picture Changes

Perimenopause

In perimenopause (typically age 45 to 52 for most women), estrogen levels are erratic rather than consistently low. Vaginal dryness and dyspareunia may appear episodically. You may still be having periods. If you use low-dose vaginal estrogen during perimenopause, you will also need contraception if you are not ready to conceive, because estrogen fluctuation can still support ovulation.

Early Postmenopause (Within 5 Years of Final Period)

This is the window where treatment is most effective at reversing tissue changes rather than just managing symptoms. Starting vaginal estrogen within the first few years after menopause prevents the most severe end-stage tissue changes, including introital stenosis.

Late Postmenopause (More Than 10 Years After Final Period)

Tissue changes are more pronounced. Treatment still works but may require a longer induction period (daily application for six to twelve weeks before switching to maintenance dosing) and may need to be combined with physical therapy for pelvic floor dysfunction. Vaginal dilators used alongside estrogen improve outcomes for women with significant introital narrowing.

Cancer Survivors

Women with estrogen-receptor-positive breast cancer represent the highest-need, lowest-treatment group. GSM is nearly universal in this population given chemotherapy-induced ovarian failure, aromatase inhibitor therapy, and restrictions on systemic hormones. The American Cancer Society notes that non-hormonal approaches should be first-line in this group, but low-dose vaginal estrogen may be considered in women with severe, refractory symptoms after discussion with their oncologist.

Prasterone and ospemifene have theoretical advantages in breast cancer survivors given their receptor selectivity, but head-to-head oncological safety data are lacking. This is an area where the evidence gap is real. Direct data in breast cancer survivors from prospective trials is thin; most guidance is extrapolated from observational data.

Pregnancy, Postpartum, Lactation, and Contraception

GSM, by definition, is a condition of estrogen deficiency and does not occur in pregnancy. Pregnant women should not use vaginal estrogen therapy. Low-dose vaginal estrogen has not been studied in pregnancy, and any exogenous estrogen exposure in pregnancy carries theoretical risk to fetal development. If you are pregnant and experiencing vaginal discomfort, tell your OB-GYN; safe non-hormonal lubricants and moisturizers are appropriate.

Postpartum and breastfeeding. Lactation produces a hypoestrogenic state that closely mimics menopause. Vaginal dryness, pain with intercourse, and urinary frequency are common. These symptoms are physiological and typically resolve within weeks to months after weaning. Non-hormonal vaginal moisturizers are the safest first approach during breastfeeding. Low-dose vaginal estrogen is not well-studied in lactating women, and transfer to breast milk has not been excluded. Most clinicians recommend avoiding it until after weaning unless symptoms are severe and a shared decision is made with your provider.

Contraception note for perimenopausal women. If you are perimenopausal and using vaginal estrogen, remember that you may still ovulate. Vaginal estrogen is not a contraceptive. Use a reliable contraceptive method until you have had 12 consecutive months without a period, which is the clinical definition of menopause. Condoms, a hormonal IUD, or progestin-only methods are options that do not interfere with GSM treatment.

Ospemifene and pregnancy. Ospemifene is a SERM and is teratogenic in animal studies. It should not be used during pregnancy or by women who may become pregnant. Reliable contraception is required if there is any chance of pregnancy.

Who GSM Treatment Is Right For (and Who Should Use Caution)

Good Candidates for Low-Dose Vaginal Estrogen

• Postmenopausal women with moderate to severe vaginal dryness, dyspareunia, or urinary frequency
• Women with recurrent UTIs attributed to urogenital atrophy
• Women who cannot tolerate or do not need systemic hormone therapy but have genitourinary symptoms

Women Who Should Discuss Risks Carefully First

• Women with a personal history of estrogen-receptor-positive breast cancer (discuss with oncologist)
• Women with unexplained postmenopausal bleeding (bleeding must be evaluated before starting any estrogen)
• Women with a history of endometrial cancer (discuss with gynecologic oncologist; low-dose vaginal estrogen with minimal systemic absorption may be appropriate in some cases)
• Women with active or recent venous thromboembolism (low-dose vaginal estrogen is generally considered safe given minimal absorption, but discuss risk)

Women for Whom Non-Hormonal Options Are Preferred First

• Breastfeeding women with postpartum vaginal dryness
• Women with active estrogen-receptor-positive breast cancer on treatment
• Women who have a strong personal preference to avoid any hormonal product

Managing GSM Day to Day: Practical Steps

Good GSM management combines prescription treatment with daily habits.

Keep the vulvar environment gentle. Avoid scented soaps, feminine hygiene sprays, and bath products that raise vaginal pH or cause irritation. Rinse with water only externally.

Wear breathable fabrics. Cotton underwear and loose clothing reduce friction and moisture trapping.

Maintain sexual activity or use dilators. Regular sexual activity or dilator use maintains vaginal caliber and blood flow. There is no clinical recommendation to avoid sex with GSM; in fact, regular activity supports tissue health.

Use vaginal moisturizers regularly, not just when symptomatic. Replens or hyaluronic acid gel used consistently two to three times per week is more effective than using it only when discomfort is acute.

Ask about pelvic floor physical therapy. A pelvic floor PT can address co-existing hypertonic pelvic floor dysfunction, which is common in women with dyspareunia, and teach dilator use. This is underused and highly effective.

Track your symptoms. Keep a simple symptom diary of dryness, pain with intercourse (score 0 to 10), urinary urgency frequency, and any bleeding. This helps your clinician assess treatment response at follow-up.

The Evidence Gap: What We Don't Yet Know

Women have been historically under-represented in urological and sexual health trials. Most GSM trials enroll naturally postmenopausal women in their early to mid-50s. Data are thinner in women aged 70 and older, women with surgical menopause at younger ages, women with primary ovarian insufficiency (POI), and breast cancer survivors. Extrapolation from the main trial populations to these groups is common but not always validated.

Long-term data beyond 12 to 24 weeks of vaginal estrogen use are also limited. Most trials are 12-week endpoints. Clinicians and patients make decisions about years-long maintenance dosing based on short-term efficacy data and reassuring pharmacokinetic profiles, not on decade-long outcome studies.

This is not a reason to avoid treatment. The benefit-to-risk ratio for low-dose vaginal estrogen in most postmenopausal women without contraindications is favorable by consensus of major societies. But honest acknowledgment of these gaps matters for shared decision-making.